Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Chia-Yun Wu, Liang-Tsai Hsiao, Tzeon-Jye Chiou, Jyh-Pyng Gau, Jin-Hwang Liu, Yuan-Bin Yu, Yi-Tsui Wu, Chia-Jen Liu, Yu-Chung Huang, Man-Hsin Hung, Po-Min Chen, Yi-Hsiang Huang & Cheng-Hwai Tzeng. (2015) Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. Leukemia & Lymphoma 56:8, pages 2357-2364.
Read now
Read now
Martin Dreyling & Christian Schmidt. (2010) Rituximab in relapsed aggressive lymphoma: play it again, Sam?. Leukemia & Lymphoma 51:3, pages 355-356.
Read now
Read now
Articles from other publishers (15)
Ewa Paszkiewicz‐Kozik, Wojciech Michalski, Michał Taszner, Monika Mordak‐Domagała, Joanna Romejko‐Jarosińska, Wanda Knopińska‐Posłuszny, Jacek Najda, Anna Borawska, Monika Chełstowska, Monika Świerkowska, Anna Dąbrowska‐Iwanicka, Agata Malenda, Agnieszka Druzd‐Sitek, Robert Konecki, Beata Kumiega, Michał Osowiecki, Beata Ostrowska, Tomasz Szpila, Marcin Szymański, Łukasz Targoński, Katarzyna Domańska‐Czyż, Lidia Popławska, Sebastian Giebel, Andrzej Lange, Andrzej Pluta, Jan Maciej Zaucha, Grzegorz Rymkiewicz & Jan Walewski. (2022) Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma. British Journal of Haematology 198:1, pages 73-81.
Crossref
Crossref
Yoriko Yamashita-Kashima, Keigo Yorozu, Takaaki Fujimura, Natsumi Kawasaki, Mitsue Kurasawa, Shigeki Yoshiura, Naoki Harada, Osamu Kondoh & Yasushi Yoshimura. (2022) Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors. International Journal of Hematology 115:6, pages 860-872.
Crossref
Crossref
Natsumi Kawasaki, Yoriko Yamashita-Kashima, Takaaki Fujimura, Shigeki Yoshiura, Naoki Harada, Osamu Kondoh & Yasushi Yoshimura. (2022) Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies. Molecular Biology Reports 49:6, pages 4421-4433.
Crossref
Crossref
David Qualls & Gilles Salles. (2022) Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 107:1, pages 19-34.
Crossref
Crossref
Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, Shigeki Yoshiura, Naoki Harada & Yasushi Yoshimura. (2021) Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells. Molecular Cancer Therapeutics 20:6, pages 1133-1141.
Crossref
Crossref
Gilles Salles. (2020) How do I sequence therapy for follicular lymphoma?. Hematology 2020:1, pages 287-294.
Crossref
Crossref
Sharad Khurana, Salman Ahmed, Victoria R Alegria, Sonikpreet Aulakh, Meghna Ailawadhi, Anshika Singh, Asher Chanan-Khan & Sikander Ailawadhi. (2019) Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia. SAGE Open Medical Case Reports 7, pages 2050313X1882391.
Crossref
Crossref
Manaka Muneishi, Ayaka Nakamura, Katsumi Tachibana, Junko Suemitsu, Shinji Hasebe, Kazuto Takeuchi & Yoshihiro Yakushijin. (2017) Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics. International Journal of Clinical Oncology 23:2, pages 375-381.
Crossref
Crossref
Mengyao Li, Nimita Dave, Ahmed Hamed Salem & Kevin J. Freise. (2017) Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients. Medicine 96:35, pages e7988.
Crossref
Crossref
Laurie H. SehnAndre GoyFritz C. OffnerGiovanni MartinelliM. Dolores CaballeroOle GadebergTara BaetzAndrew D. ZelenetzGianluca GaidanoLuis E. FayadRena BucksteinJonathan W. FriedbergMichael CrumpBranimir JaksicPier Luigi ZinzaniSwaminathan Padmanabhan IyerDeniz SahinAkiko ChaiGünter Fingerle-RowsonOliver W. Press. (2015)
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20
+
Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
. Journal of Clinical Oncology 33:30, pages 3467-3474.
Crossref
Crossref
Man-Hsin Hung, Yuan-Bin Yu, Liang-Tsai Hsiao, Ying-Chung Hong, Jin-Hwang Liu, Jyh-Pyng Gau, Tzeon-Jye Chiou, Po-Min Chen, Cheng-Hwai Tzeng & Chun-Yu Liu. (2013) Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure. Journal of the Chinese Medical Association 76:4, pages 195-200.
Crossref
Crossref
Berna Bozkurt Duman, Berksoy Şahin, Melek Ergin & Birol Guvenc. (2011) Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature. Medical Oncology 29:2, pages 1223-1226.
Crossref
Crossref
Liat Vidal, Anat Gafter-Gvili, Gilles Salles, Martin H. Dreyling, Michele Ghielmini, Shu-Fang Hsu Schmitz, Ruth Pettengell, Mathias Witzens-Harig & Ofer Shpilberg. (2011) Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials. JNCI: Journal of the National Cancer Institute 103:23, pages 1799-1806.
Crossref
Crossref
Bertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie-Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri A Elsayed & Pier Luigi Zinzani. (2011) Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology 12:8, pages 773-784.
Crossref
Crossref
Hye J KANG, Seung S LEE, Kyeong M KIM, Tae H CHOI, Gi J CHEON, Won S KIM, Cheolwon SUH, Sung H YANG & Sang M LIM. (2011) Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Asia-Pacific Journal of Clinical Oncology 7:2, pages 136-145.
Crossref
Crossref